Abstract
SummaryThis article intends to summarize personal non-small cell lung cancer (NSCLC) highlights of the ESMO 2019 meeting. Again, immunotherapy in the first-line setting of wildtype NSCLC was a major aspect and the search of the optimal biomarker for therapy stratification continues. Moreover, important data on the use of osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor in the first-line setting of EGFR-mutated NSCLC were presented, emerging as the preferred therapeutic strategy in these patients. The ideal treatment sequence, however, remains discussed controversially. The treatment of rare genetic alterations was another important topic, covering updated data on effective NTRK and ROS1 inhibition. In conclusion, ESMO 2019 fueled the lung cancer community with inspiring new data, contributing to a more individualized, hopefully improved lung cancer treatment and continuing to decrease lung cancer mortality.
Highlights
ESMO 2019 took place in Barcelona from 27 September to 1 October 2019 and again, treatment of nonsmall cell lung cancer (NSCLC) was a major aspect of the meeting
The independent co-primary endpoints of the study focused on comparing nivolumab plus ipilimumab versus chemotherapy and comprised progression-free survival (PFS) in a high tumor mutational burden (TMB) population (i.e., >10 mut/Mb) and overall survival (OS) in the PD-L1 ≥1% population
Data on the co-primary endpoint PFS had already been published before ESMO 2019 and showed a significant PFS benefit for nivolumab plus ipilimumab in patients with a high TMB compared to chemotherapy
Summary
ESMO 2019 took place in Barcelona from 27 September to 1 October 2019 and again, treatment of nonsmall cell lung cancer (NSCLC) was a major aspect of the meeting. The congress was held under the tagline “Translating science into better cancer patient care” and intended to bridge basic research and clinical–oncological therapy. Due to better treatment options and the plethora of highly effective drugs, the discussion on the right treatment sequence becomes overt and increasingly important to further improve patient care
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
